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1. Introduction 
During the middle of the 20th century, Chanock and co-workers recovered an 
cytopathogenic agent from lung secretions of young infants with lower respiratory tract 
disease (LRTD). This agent was found out to be similar to an agent that was identified in an 
outbreak of infection in chimpanzees resembling the common cold (Chanock et al, 1957; 
Morris J.A. et al, 1956). Because of its characteristic cytopathologic findings in tissue culture 
where it forms syncytia of epithelial cells, the virus was named respiratory syncytial virus 
(Chanock et al, 1957). From serological studies it was observed that almost all children have 
been infected by RSV by the age of two years (Glezen et al, 1986). Since then, RSV has been 
identified as the most important causative agent of viral LRTD (Hall, 2001). Approximately 
100.000 infants are annually admitted with RSV induced bronchiolitis in the United States, 
and the number of hospitalizations is increasing (Shay et al, 1999). Because of this, RSV 
associated disease imposes a major burden on health care resources (Leader et al, 2003). 
Furthermore, RSV is increasingly being recognized as an important pathogen causing severe 
LRTD in elderly and immunocompromised patients (Falsey et al, 2005). 
This chapter reflects on the current knowledge about RSV in critically ill children admitted 
to the pediatric intensive care unit (PICU) and its possible therapeutic options. 
2. Epidemiology of RSV 
RSV (genus pneumoviridae, family of paramyxoviridae) is a single stranded enveloped RNA 
virus. The RSV genome codes for ten major proteins (Hacking et al, 2002). Of these proteins, 
the F (fusion) and the G (attachment) glycoprotein are the major surface antigenic 
determinants. Two antigenic strains of RSV, group A and group B, can be identified. Both 
groups co-circulate together but also independently from each other during annual 
epidemics (Hall et al, 1990). The clinical spectrum of RSV associated disease extends from 
mild upper respiratory tract infection to severe lower respiratory tract infection including 
bronchiolitis and pneumonia (Hall, 2001). Re-infections occur frequently, although they tend 
to be mild (Henderson et al, 1979).  
Severe RSV infection necessitating mechanical ventilation (MV) occurs in 2 – 16% of 
previously healthy infants (Leclerc et al, 2001). This percentage may increase up to 30 – 35% 
among high-risk patients such as children with congenital heart disease (CHD), chronic lung 
disease (CLD), compromised immune function, postnatal age less than 6 weeks and 
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premure birth (i.e. less than 37 weeks gestational age) (Wang et al, 1996). The mean duration 
of conventional MV may be as long as 10 days, but in a proportion of ventilated patients 
alternatives mode such high-frequency oscillatory ventilation (HFOV) or extra-corporeal 
membrane oxygenation (ECMO) are necessitated when severe impaired oxygenation or 
ventilation persists (Guerguerian et al, 2004; Leclerc et al, 2001). Usually mortality rates are 
less than 1% for previously healthy infants, although these percentages may increase up to 
10% among high-risk infants (Shay et al, 2001). 
3. Clinical manifestations of RSV in the PICU 
RSV LRTD is usually referred to as “bronchiolitis” because of the clinical presence of 
audible airflow limitation on expiration in a significant proportion of infected infants and 
the classic hyperinflation on chest radiograph. In infants admitted to the PICU an increase in 
total respiratory system resistance compatible with obstructive disease has also been 
demonstrated (Gauthier et al, 1998; Hammer et al, 1995; Hammer et al, 1997; Mallory Jr et al, 
1989). Nevertheless, RSV LRTD is in fact a heterogeneous disease, implicating that it is 
incorrect to label all RSV LRTD as bronchiolitis (Isaacs, 1998). This is of importance because 
of the proposed differences in ventilatory strategies needed to treat obstructive or restrictive 
disease (Frankel et al, 1999). Furthermore, identification of the clinical phenotype aids in 
targeting a specific population of infants for a therapeutic modality.  
In critically ill children RSV LRTD can also be characterized as a restrictive disease (Frankel 
et al, 1999). Hammer and co-workers evaluated 37 mechanically ventilated infants with RSV 
and were able to categorize them as having obstructive or restrictive disease based upon the 
findings from pulmonary function testing (PFT) (Hammer et al, 1997). Ten infants had 
decreased respiratory system compliance (Crs) compatible with restrictive disease in 
conjunction with four-quadrant alveolar consolidation on chest radiograph compared to 
healthy controls. The remaining 27 had increased respiratory system resistance (Rrs), 
compatible with obstructive disease. Infants with restrictive disease required prolonged 
ventilation compared to infants with obstructive disease. However, infants with underlying 
diseases such as prematurity and/or chronic lung disease were not excluded in their 
analysis. Especially among infants with restrictive disease there were three infants with 
CLD. By including these infants, it cannot be ruled out they had pre-existing lung 
abnormalities that might contribute to altered respiratory system mechanics. For instance, 
prematurely born infants with CLD have higher Rrs that predisposed them to suffer from 
symptomatic RSV LRTD compared to controls (Broughton et al, 2006). Hence, the issue of 
clinical phenotype is still subject of scientific debate.  
Unfortunately, in most PICU’s PFT is not done routinely. Alternatively, ventilatory indices 
characterizing the efficacy of gas exchange might be used. These include the oxygenation 
index (OI) and the alveolar-arterial oxygen gradient (Aa-DO2). Tasker and co-workers found 
an Aa-DO2 > 400 mmHg during the first 24 hours of mechanical ventilation and mean 
airway pressure (MAP) > 10 cm H2O associated with radiographic appearances suggestive 
of RSV restrictive disease (Tasker et al, 2000). All infants were previously healthy, and had 
upon PICU admission four-quadrant alveolar consolidation on their chest radiograph. 
However, their definition of severe RSV LRTD was based upon a chest radiograph scoring 
system developed for prematurely born infants with infant respiratory distress syndrome 
(IRDS) and has not been validated for patients with RSV to our knowledge (Maconochie et 
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al, 1991). Furthermore, their findings have not been validated yet. We have retrospectively 
studied parameters for gas exchange in 53 mechanically ventilated infants with RSV LRTD 
admitted between 1995 and 2005, and were unable to detect significant differences in 
oxygenation index (OI) or alveolar-arterial oxygen gradient (Aa-DO2) between infants with 
radiological classified restrictive disease and obstructive disease (manuscript in 
preparation). We further observed a comparable duration of MV between infants with 
obstructive and restrictive disease. Our findings strengthen our assumption that RSV LRTD 
is a heterogeneous disease that cannot be strictly dichotomized into a restrictive and 
obstructive disease. 
RSV is also a neurotrophic virus. Our group has found that it causes apnoea (defined by a 
cessation of respiration or a bradycardia with accompanying cyanosis for a period of 20 
seconds or longer) in approximately one out of every five patients presenting with RSV 
(Kneyber et al, 1998). In fact, apnoea may be the presenting symptom without any other 
symptoms of respiratory tract infection. The odds for MV were 6.5-fold increased among 
infants who present with RSV – associated apnoea. The exact mechanism underlying RSV-
associated apnoea is unknown, although it has been observed that the apnoea is of central 
origin (Rayyan et al, 2004).  
Cardiovascular compromise during RSV infection has been reported by various authors. 
Severe RSV infection may mimic shock (Njoku et al, 1993). Nearly half of all infants 
admitted to the PICU were found to have elevated cardiac enzyme levels (Checchia et al, 
2000; Eisenhut et al, 2004). Cardiovascular support either by fluid boluses or inotropic drug 
use is not seldomly necessitated in ventilated infants (Checchia et al, 2000; Eisenhut et al, 
2004; Kim et al, 1997). Life-threatening disturbances of the cardiac rhythm have also been 
described in critically ill patients with RSV (Playfor et al, 2005; Thomas et al, 1997). 
There is much controversy whether or not severe RSV infection is associated with increased 
occurrence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). One 
group of investigators have reported that 33% infants admitted to the PICU developed 
hyponatraemia (serum sodium < 136 mmol/L) (Hanna et al, 2003). Four of them had a 
hyponatraemic seizure upon PICU admission. Van Steensel-Moll and co-workers observed 
increased ADH levels in mechanically ventilated children compared with non-ventilated 
children (Steensel-Moll et al, 1990). However, these were not significantly correlated with 
serum sodium levels.  
4. Bacterial co-infections 
Many if not all infants admitted to the PICU with RSV LRTD have antibiotics prescribed. 
Clinicians often assume that a concurrent bacterial pulmonary infection is probably 
(partially) accountable for the development of respiratory failure due to RSV. Nevertheless, 
the occurrence of severe infections is low. Randolph et al retrospectively studied the number 
of positive cultures from blood, urine, cerebrospinal fluid and endotracheal aspirates upon 
PICU admission among 63 mechanically ventilated previously healthy infants (Randolph et 
al, 2004). All of these infants were treated with antibiotics. They observed a low percentage 
(< 2%) of concurrent bacterial blood stream infection. In addition, 24 (38.1%) had positive 
cultures from endotracheal aspirates that could be linked to either possible or probable 
bacterial pneumonia. These observations were supported by the findings of Bloomfield et al 
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(Bloomfield et al, 2004). They observed bacteraemia in 6 children out of 208 PICU 
admissions. Four infants were mechanically ventilated. All of them were prematurely 
born or had congenital heart disease. Our group has also studied retrospectively the 
occurrence of concurrent bacterial infection in 65 mechanically ventilated infants during 
1996 – 2001 (Kneyber et al, 2005a). In 38 of these infants microbiological investigations 
were performed. All had antibiotics upon PICU admission. We found only one positive 
culture from blood and 37.5% positive cultures from endotracheal aspirates compatible 
with bacterial pneumonia. Infants with concurrent bacterial infection had similar CRP 
concentrations and white blood cell counts compared to infants with negative cultures. In 
addition, the presence of bacterial pulmonary infection upon PICU admission was 
undetectable by the OI as this was equal among infants with and without positive 
cultures. There were two additional remarkable finding from our study. First, concurrent 
bacterial infection occurred almost exclusively in previously healthy, term born infants. 
Second, infants with positive concurrent bacterial infection required prolonged 
ventilatory support (14.3 ± 2.4 versus 10.6 ± 1.0 days). 
All retrospectively made observations were confirmed by a study from Thorburn et al 
(Thorburn et al, 2006). Their group prospectively collected endotracheal aspirates in 165 
mechanically ventilated infants during three consecutive RSV seasons. They observed that 
21.8% had concurrent bacterial pneumonia upon PICU admission. Strikingly, these infants 
also required prolonged ventilatory support compared to infants without bacterial 
pneumonia. Only 36% of these infants had antibiotics on PICU admission. The majority of 
bacterial pneumonias occurred in infants with pre-existing morbidity. 
It may thus be concluded that at least in (significant) proportion of infants hospitalised to 
the PICU with severe RSV LRTD a bacterial pneumonia (partially) contributes to the 
development of respiratory failure. Whereas others report such findings among children 
with pre-existing morbidity, we were unable to confirm this. At present therefore, it seems 
rational to refrain from the routine use of antibiotics in children admitted to the PICU. 
Immediate investigation of the endotracheal aspirate may identify those children in whom 
antibiotics are justified, although this hypothesis calls for further study such as a 
randomized controlled trial. 
5. Pathophysiology 
The pathophysiological mechanisms underlying RSV-induced respiratory failure with 
subsequent necessitation of MV are not fully elucidated. Various pathways can be proposed 
that most likely interact with each other, including viral load and strain, pre-exististing 
structural abnormalities and the host immune response. Pre-existing structural 
abnormalities of the respiratory system may predispose prematurely born children and 
children with CLD or CHD to a severe disease course. Prematurely born but otherwise 
healthy infants have an underdeveloped respiratory system that is easily compromised by 
the direct toxic effects of an infectious agent, such as epithelial necrosis due to invading 
virus (Welliver, 2003). Young children with CLD have structural abnormal airways that 
collapse easily as well as structural pulmonary abnormalities predisposing them to severe 
disease necessitating MV (Welliver, 2003).  
Viral strain is not accountable for disease severity. We observed that the need for PICU 
admission and MV is equally distributed among infants with RSV group A and B (Kneyber 
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et al, 1996). In contrast, the effect of viral load on disease severity is less clear. Conflicting 
data have been reported on differences in viral load between ventilated and non-
ventilated infants. DeVincenzo et al were unable to find significant differences in viral 
load obtained from nasal washes between previously healthy ventilated (n = 22) and non-
ventilated infants (n = 119) (5.185 versus 4.963 log pfu/mL) (DeVincenzo et al, 2005). 
Others, however, observed significantly higher nasal viral load among ventilated (n = 15) 
versus non-ventilated previously healthy infants (n = 24) (5.06 ± 0.34 vs. 3.91 ± 0.35 log 
pfu/mL, p = .022) (Buckingham et al, 2000). Only one group of investigators has 
exclusively focused on differences in viral load among ventilated infants. Van Woensel et 
al found a higher viral load in tracheal aspirates of infants (n = 14) who met criteria for 
“severe RSV LRTD” (PaO2/FiO2 ratio  200 mmHg and a mean airway pressure (MAP) > 
10 cmH2O (72.0 ± 28.0 RNA copies) compared to infants (n = 8) with “mild” disease (21.1 
± 9.2 RNA copies, p = .20) (van Woensel et al, 2003a). At present, there are no reports on 
differences in viral load among various categories of mechanically ventilated high-risk 
infants. Further studies are awaited. 
Various authors have postulated that the immune response against RSV plays an important 
role in determining disease severity, especially when there is no pre-existing disease (Bont et 
al, 2002). It is subject of debate whether or not the immune response against RSV is 
protective or disease-enhancing. Results from animal studies have led to the assumption 
that an overshoot of the T-cell response towards a T – helper 2 profile may be responsible for 
severe disease (Cannon et al, 1988). This skwewing towards a T – helper 2 response has not 
been universally confirmed to occur in children with RSV LRTD (Bont et al, 2002).  
A good humoral immune response is necessary to prevent severe RSV LRTD. Low titers of 
neutralising antibodies have been found to be associated with severe RSV LRTD (Glezen et 
al, 1981; Karron et al, 1999). Yet, this may specifically apply for infants born prematurely as 
in general they lack sufficient titers of protective immunoglobulin G neutralising antibodies 
because placental transport of IgG occurs late in gestation, near the end of the third 
trimester. Early post-natal life is associated with a physiological immune deficiency defined 
by hyporesponsiveness of mononuclear phagocytes to stimuli and a diminished T – cell 
response (Marchant et al, 2005; Marodi, 2006). This low level of immune response could 
very young previously healthy infants render susceptible for severe disease. 
Next to this, a good cellular immune response is also necessary to prevent severe RSV 
LRTD. Low numbers of T – cells are found in peripheral blood samples of ventilated infants 
compared to non-ventilated infants, although this also may suggest recruitment of activated 
T – cells to the lungs (de Weerd et al, 1998). More importantly, low levels of IFN- (a T – 
helper 1 cell cytokine) were found in nasopharyngeal aspirates of mechanically ventilated 
children compared to non-ventilated children (Bont et al, 2001). In addition, monocyte-
derived interleukin (IL) 12 was observed to be inversely related to the duration of MV. IL-12 
promotes the differentiation of naïve CD4 –positive T cells into T-helper 1 cells (Ramshaw et 
al, 1997). Finally, mononuclear cells of ventilated infants exhibited diminished ex-vivo 
lymphoproliferative responses and the capacity to produce IFN- and IL-4 compared to non-
ventilated infants.  
It may thus be concluded that severe RSV LRTD in healthy term and pre-term born infants 
originates from an immature immune system so that they cannot neutralise the virus 
sufficiently. For children with pre-existing abnormalities of the respiratory system it is 
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probably the combination of both. In addition, it cannot be ruled out that genetic 
polymorphisms also play an important role in the host susceptibility for severe RSV LRTD. 
Future research should be directed towards understanding the pathophysiological 
mechanisms underlying severe RSV LRTD and are eagerly awaited. 
6. Treatment of severe RSV LRTD 
Therapeutic management of mechanically ventilated infants with severe RSV LRTD can 
either be curative or supportive. Curative treatment includes the virostatic drug ribavirin or 
corticosteroids, whereas bronchodilators and exogenous surfactant are supportive.  
Three reports reporting the efficacy of ribavirin were reviewed systematically in a Cochrane 
review (Randolph et al, 2000). Results from a total number of 104 mechanically ventilated 
infants were pooled. The use of ribavirin was associated with a significant decrease in the 
duration of MV (mean difference 1.2 days (95% confidence interval -.2 to -3.4, p = 0.03). 
Normal saline was used as placebo in two studies, whereas sterile water was used in the 
third study. However, the beneficial effect of ribavirin was discarded when the one study 
using sterile water instead for normal saline for control was excluded from analysis. This 
could be explained by the serious side-effect of sterile water, being induction of 
bronchospasmn. Thus, there is not rationale for the use of ribavirin. Furthermore, is not easy 
to administer and is associated with teratogenic side-effects.  
Others have explored the efficiacy of corticosteroids (Buckingham et al, 2002; van Woensel 
et al, 1997; van Woensel et al, 2003b; van Woensel et al, 2011). Unfortunately, the results of 
these studies cannot be easily compared because of the different dosing and duration of 
treatment. Van Woensel et al initially performed a post-hoc analysis of 14 mechanically 
ventilated infants in their original trial of prednisolone 1 mg/kg for seven days versus 
placebo in hospitalised children with RSV (van Woensel et al, 1997). They observed a non-
significant difference in mean duration of MV (4.7 ± 2.91 versus 6.3 ± 4.23 days). 
Subsequently, they designed a randomised clinical trial in mechanically ventilated infants 
comparing dexamethason 0.15 mg/kg/day every 6 hours for 48 hours with placebo in 85 
patients (van Woensel et al, 2003b). No significant difference in mean duration of MV 
between the two treatment arms was found. Yet, post-hoc analysis suggested that 
corticosteroids might be beneficial among ventilated infants who met criteria for mild 
disease as derived by Tasker et al (Tasker et al, 2000). Similar results were obtained in a 
study including 41 mechanically ventilated infants (Buckingham et al, 2002). Recently, Van 
Woensel et al have completed a third RCT (the so-called STAR-trial) based upon the post-
hoc analysis from their second RCT (van Woensel et al, 2011). Eighty-nine patients were 
stratified according to oxygenation abnormalities: PaO2/FiO2 < 200 and MAP > 10 cmH2O 
(N = 45) vs PaO2/FiO2 >200 and MAP < 10 cmH2O (N = 44) and randomized to either 
dexamethason 0.15 mg/kg/day every 6 hours for 48 hours with placebo. The study showed 
that the duration of MV was not significantly reduced in both stratification arms by 
dexamethason. Hence, the use of corticosteroids cannot be supported. 
The efficacy of bronchodilators for ventilated infants with RSV LRTD has been explored in 
three different studies (Derish et al, 1998; Hammer et al, 1995; Mallory, Jr. et al, 1989). 
Mallory and co-workers observed a ≥ 30% improvement of peak expiratory flow at 25% 
(MEF25) of functional residual capacity (FRC) in 13 out of 14 mechanically ventilated 
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children with RSV LRTD (Mallory, Jr. et al, 1989). Pulmonary function was assessed by 
deflation flow-volume curve analysis. Hammer et al performed a more elegant study by 
excluding infants with restrictive disease (Hammer et al, 1995a). However, only 10 out of 20 
infants with obstructive RSV LRTD responded to nebulised albuterol (defined by a ≥ 2-fold 
improvement of intra-individual coefficient of variation for MEF25 en Rrs. Derish et al 
included 25 infants and observed a significant increase in PEF at FRC and decrease in Rrs in 
some patients (Derish et al, 1998). Of note, all three studies incorporated infants with pre-
existing morbidity, and none were designed to detect an effect on the duration of MV 
and/or PICU stay. The routine use of bronchodilators, therefore, seems unjustified. 
Recently, Levin and co-workers confirmed the absence of beneficial effect of bronchodilators 
(i.e. norepinephrine, levalbuterol, and racemic albuterol) (Levin et al, 2008). 
Low levels of surfactant phospholipids and proteins as well as a diminished function of 
surfactant (lowering surface tension at the alveolar-capillary level) has been described 
(Kneyber et al, 2005b). Hence, the the use of exogenous surfactant seems highly rational. Its 
effect on disease course has been explored in three RCTs (Luchetti et al, 1998; Luchetti et al, 
2002; Tibby et al, 2000). The group of Luchetti et al performed two studies investigating 
porcine surfactant versus no placebo (Luchetti et al, 1998; Luchetti et al, 2002). In their first 
study 20 children with bronchiolitis of whom 20% were RSV positive were randomized to 
receive either 50 mg/kg porcine surfactant once, or nothing (Luchetti et al, 1998). In their 
second, and methodologically more sound, study 40 children with RSV LRTD were 
randomized (Luchetti et al, 2002). Not only oxygenation improved in both studies, but the 
mean duration of MV was also significantly different between the surfactant and the 
placebo group (4.4 ± .4 vs 8.9 ± 1.0 days in the first study and 4.6 ± .8 vs 5.8 ± .7 days in the 
second study). These findings were confirmed by a study by Tibby et al, randomizing 19 
infants to receive either 100 mg/kg bovine surfactant twice or air placebo (Tibby et al, 2000). 
Furthermore, a trend towards a reduced duration of MV was observed (126 hours vs 170 
hours in the control group). Taken together, the findings of these three studies strongly call 
for a RCT with duration of MV as primary endpoint. 
MV remains the mainstay of supportive therapy for infants with RSV – induced respiratory 
failure. Interestingly, there are no randomized controlled trials (RCT) on for instance various 
ventilatory strategies (volume controlled versus pressure controlled) or the level of 
positive end-expiratory pressure (PEEP) (Leclerc et al, 2001). MV with heliox has been 
scantily studied among infants with RSV LRTD. From a pathophysiological point of view 
MV with heliox seems rational. Heliox has a density that is one-seventh that of air, 
resulting in a decreased resistance to gas flow (Gupta et al, 2005). There is one trial 
investigating the effect of MV with heliox in various concentrations in ten infants with 
RSV LRTD (Gross et al, 2000). No beneficial effect could be demonstrated. As the study 
has methodological flaws, and no attempt was made to discriminate clinical phenotype of 
RSV LRTD, the role of MV with heliox requires further study. Our group has undertaken 
a pilot-study in 13 ventilated infants with RSV LRTD. Heliox 60/40 (i.e. 60% helium and 
40% oxygen in the inspired gas) significantly reduced the Rrs compared with 
conventional gas mixture although CO2 exchange was not improved (Kneyber et al, 2009). 
Our findings warrant follow-up in a large RCT. 
Until now, the mainstay of therapy for mechanically ventilated infants with RSV LRTD has 
been symptomatic. Judging the outcomes of the various RCTs, it is highly unlikely that this 
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will change in the near future. The only promising therapeutic modality seems exogenous 
surfactant, although this has no direct curative effect.  
7. Prevention 
Vaccination against RSV will not readily be available, but passive immunisation can be 
applied (Kneyber et al, 2004). Passive immunization can be achieved through 
palivizumab, which is a monoclonal antibody directed against the F – glycoprotein. 
Presently, its use is advised for (a) infants not older than 12 months without CLD born 
after a gestation of 28 weeks, (b) infants not older than six months without CLD born after 
a gestation of 29 to 32 weeks, and (c) infants born after a gestation of 32 to 35 weeks with 
at least two of the following risk factors: attending child care, having school-aged siblings, 
being exposed to environmental air pollutants, having congenital abnormalities of the 
airways, or being diagnosed with severe neuromuscular disease. Palivizumab is also 
advised for children younger than two years of age with CLD or a hemodynamically 
significant CHD (Meissner et al, 2003). 
The effect of routine passive immunization on the number of PICU admissions as well as 
duration of MV is not clear. In the IMpact study an overall reduction of 55% in 
hospitalizations was found among palivizumab recipients (N = 1002 vs 500 controls). 
However, the number of PICU admissions (1.3% vs 3%) or number of mechanically 
ventilated children (0.2% vs .7%) was not significantly affected (The IMpact-RSV Study 
Group, 1998). Children with congenital heart disease were separately studied (639 
palivizumab recipients vs 648 controls) (Feltes et al, 2003). Again, the overall reduction of 
45% in hospitalizations was not observed for the number of PICU admissions (2% vs 3.7%) 
or mechanically ventilated children (1.3% vs 2.2%). Two post-licensure studies after the 
introduction of palivizumab have been reported. Pedraz and co-workers studied the efficacy 
of palivizumab in four consecutive RSV seasons (non-prophylaxed children (N = 1583) 
admitted between 1998 – 2000, and prophylaxed (N = 1919) children admitted between 2000 
– 2002) in Spain (Pedraz et al, 2003). The number of children admitted to the PICU (13% vs 
20%) or requiring MV (8% vs 11%) were comparable. Similar observations were made in a 
national survey performed in Israel during two consecutive RSV seasons (2000 – 2002), 
including 296 children (Prais et al, 2005). It thus seems that monthly prophylaxis with 
palivizumab does not have an effect on the occurrence of severe RSV LRTD necessitating 
PICU admission and/or MV. This suggests that not only virological and/or immunological 
factors are (partially) responsible for the development of severe RSV LRTD.  
8. Long term effects 
Long-term follow-up studies of children hospitalised with RSV LRTD have irrespective of 
age consistently shown impaired pulmonary function compared with children who had no 
apparent infecting agent, mainly characterized by an obstructive pattern (i.e. increased 
airway resistance) (Cassimos et al, 2008; Dezateux et al, 1997; Singleton et al, 2003; Stein et 
al, 1999). This increase in airway resistance coincides with episodes of recurrent wheezing 
resembling childhood asthma in up to 50% of children, and not results in a high use of 
asthma medications but also in a substantial decrease in parental-reported health-related 
quality of life of the child (Bont et al, 2000; Bont et al, 2004; Kneyber et al, 2000; Stein et al, 
2004). Importantly, in general there is no data available on pulmonary function after being 
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mechanically ventilated for RSV LRTD (Ermers et al, 2009). Mechanical ventilation is life-
saving for patients with RSV induced respiratory failure. Yet, numerous experimental 
studies have shown that mechanical ventilation induces a pulmonary inflammation that 
aggravates lung injury leading to irreversible damage. This has been labelled “double-hit 
principle“ (Tremblay et al, 1998; Tremblay et al, 2006). More specifically, lung inflammation 
and programmed cell death were enhanced by mechanical ventilation in a mouse model of 
RSV LRTD (Bem et al, 2009). 
9. Conclusion 
RSV is an important cause of serious morbidity annually occurring in paediatric critical care 
units. At present, the mainstay of therapy for mechanically ventilated infants is still 
symptomatic. The routine use of ribavirin or corticosteroids cannot be recommended. 
However, there are new and promising (supportive) treatment modalities emerging such as 
the use of exogenous surfactant or mechanical ventilation with heliox. Future research 
should also be directed towards a better understanding of the pathophysiological 
mechanisms underlying severe RSV LRTD to gain insight why infants need to ventilated 
and what the effects of mechanical ventilation in combination with RSV itself are on long 
term outcome. Only then it will be possible to develop new curative treatments and to 
identify patients who might benefit from such a treatment. In the mean time, we continue 
our endless care and devotion to these infants. 
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